A plain-language guide

von Willebrand disease

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Early map · 7 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. von Willebrand disease is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's von Willebrand disease?

Von Willebrand disease is the most common inherited bleeding disorder. It results from a shortage or malfunction of von Willebrand factor, a protein essential for normal blood clotting.

Features mapped5
Treatments mapped1
Published sources4
Last reviewed2026-08-04

Signs and symptoms

Epistaxis

Frequent nosebleeds (epistaxis) are a common form of bleeding in von Willebrand disease.

Limited evidenceSource: PMID:41902888
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:903
Notesplain_language confirmed from PMID:41902888 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:903 -> PMID:41902888 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Gastrointestinal hemorrhage

Bleeding from the gastrointestinal tract can occur in von Willebrand disease, particularly in the type 2A form.

Limited evidenceSource: PMID:41453393
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:903
Notesplain_language confirmed from PMID:41453393 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:903 -> PMID:41453393 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Abnormal platelet function

In von Willebrand disease, platelets cannot stick together and to vessel walls normally, which impairs the body's ability to stop bleeding.

Limited evidenceCurated reference: ORPHA:903
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41947822
Notesplain_language confirmed from PMID:41947822 via curation 2026-07-03 [llm:fable-5].
Last reviewed2026-07-03

Menorrhagia

Heavy menstrual bleeding (menorrhagia) is a common and characteristic symptom of von Willebrand disease.

Limited evidenceSource: PMID:41902888
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesORPHA:903
Notesplain_language confirmed from PMID:41902888 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:903 -> PMID:41902888 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Reduced von Willebrand factor activity

In von Willebrand disease, von Willebrand factor (a protein needed for normal blood clotting) is reduced or does not work properly.

Limited evidenceCurated reference: ORPHA:903
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:41947822
Notesplain_language confirmed from PMID:41947822 via curation 2026-07-03 [llm:fable-5].
Last reviewed2026-07-03

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

desmopressin

Desmopressin is used to treat von Willebrand disease by raising the body's own levels of von Willebrand factor.

Used to help with: Reduced von Willebrand factor activity.

Limited evidenceSource: PMID:41377554
The source text this rests on
“Its haemostatic potential was later recognized when it was observed to enhance endogenous levels of vWF and factor VIII, leading to its incorporation into the treatment of mild haemophilia A and von Willebrand disease (vWD).”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:41377554 via curation 2026-07-03
Last reviewed2026-07-03

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 4 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:903 · Orphanet/HPO annotations for Von Willebrand disease
PMID:41377554 · Haemostasis and beyond: The expanding role of desmopressin in intensive care.
PMID:41453393 · Von Willebrand Disease Type 2A: An Update.
PMID:41902888 · Past, Present, and Future of von Willebrand Disease.

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.